Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Colorectal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm
Large Intestinal Neoplasm
Colorectal Neoplasm

Subtype

Colorectal Neoplasm

CI-CAN-00002404Explore in graph →

Non-malignant1,784 active trials21 approved drugs382 evidence items

NCIt: C2956
MeSH: D015179

Overview
Statistics
Survival
Genomics27
Variants & evidence382
Drugs79
Trials8604
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (357)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 357 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.
· Cancer Discov · 2017 · PMID 28363909 · validated civic_curation pubmed
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
· Cancer Discov · 2018 · PMID 29431699 · validated civic_curation pubmed
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
· J Clin Oncol · 2010 · PMID 20008640 · validated civic_curation pubmed
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
· J Clin Oncol · 2011 · PMID 21502544 · validated civic_curation pubmed
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
· Lancet · 2011 · PMID 21641636 · validated civic_curation pubmed
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis.
· Colorectal Dis · 2013 · PMID 24112392 · validated civic_curation pubmed
Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.

Showing 201–225 of 357 publications

← Previous
1
…
8
9
10
…
15
Next →

· Clin Cancer Res · 2024 · PMID 38727700 · validated civic_curation pubmed

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.

· Nat Commun · 2023 · PMID 37666855 · validated civic_curation pubmed

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.

· N Engl J Med · 2025 · PMID 40961426 · validated civic_curation pubmed

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

· Acta Oncol · 2014 · PMID 24666267 · validated civic_curation pubmed

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

· Lancet Oncol · 2015 · PMID 26184520 · validated civic_curation pubmed

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

· Clin Cancer Res · 2013 · PMID 23325582 · validated civic_curation pubmed

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

· Cancer Res · 2006 · PMID 16618717 · validated civic_curation pubmed

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

· Lancet Oncol · 2011 · PMID 21163703 · validated civic_curation pubmed

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

· Br J Cancer · 2010 · PMID 20628391 · validated civic_curation pubmed

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

· BMC Cancer · 2013 · PMID 23374602 · validated civic_curation pubmed

Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.

· Oncotarget · 2015 · PMID 25788273 · validated civic_curation pubmed

P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.

· BMC Cancer · 2014 · PMID 24708484 · validated civic_curation pubmed

EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.

· Chin J Cancer Res · 2014 · PMID 24653627 · validated civic_curation pubmed

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

· J Natl Cancer Inst · 2014 · PMID 24957073 · validated civic_curation pubmed

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

· Clin Cancer Res · 2008 · PMID 18794099 · validated civic_curation pubmed

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

· BMC Cancer · 2009 · PMID 19775480 · validated civic_curation pubmed

Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.

· Am J Transl Res · 2015 · PMID 26807188 · validated civic_curation pubmed

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

· Clin Cancer Res · 2014 · PMID 24947927 · validated civic_curation pubmed

HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.

· Am J Pathol · 2010 · PMID 20363910 · validated civic_curation pubmed